-
公开(公告)号：US11912660B2
公开(公告)日：2024-02-27
申请号：US17232469
申请日：2021-04-16
IPC分类号： C07D209/56 , A61K45/06
CPC分类号： C07D209/56 , A61K45/06
摘要： The present disclosure relates to compounds that act as protein kinase inhibitors, especially RPS6K1 and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer, prostate cancer, lung cancer, and metastatic cancer.
-
公开(公告)号：US20230406804A1
公开(公告)日：2023-12-21
申请号：US18451630
申请日：2023-08-17
发明人： Jayalakshmi SRIDHAR , Frank JONES , Cheryl STEVENS
IPC分类号： C07C50/12
CPC分类号： C07C50/12
摘要： The present disclosure relates to compounds that act as protein kinase inhibitors, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer.
-
公开(公告)号：US20220378721A1
公开(公告)日：2022-12-01
申请号：US17771391
申请日：2020-10-22
IPC分类号： A61K31/122 , A61P25/28
摘要： The present disclosure relates to compounds that act as protein kinase inhibitors, especially CK1δ and/or CK1ε inhibitors, which can be used to treat a serine threonine kinase-dependent disease and condition, such as neurodegenerative diseases like Alzheimer's Disease, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for neurodegenerative diseases, including Alzheimer's disease.
-
公开(公告)号：US20210355060A1
公开(公告)日：2021-11-18
申请号：US17284432
申请日：2019-10-09
发明人： Jayalakshmi SRIDHAR , Frank JONES , Cheryl STEVENS
IPC分类号： C07C50/12
摘要： The present disclosure relates to compounds that act as protein kinase inhibitors, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer.
-
5.发明授权公开(公告)号：US09650369B2
公开(公告)日：2017-05-16
申请号：US14431789
申请日：2013-09-27
发明人： Guangdi Wang , Quan Jiang , Qiu Zhong , Qiang Zhang , Shilong Zheng
IPC分类号： C07D417/12 , C07D277/18 , C07D277/44 , A61K31/426 , A61K31/427 , C07D277/40 , C07D277/46 , A61K45/06 , A61K31/4439 , C07D277/52
CPC分类号： C07D417/12 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K45/06 , C07D277/40 , C07D277/44 , C07D277/46 , C07D277/52 , A61K2300/00
摘要： Thiazole analog compounds and their pharmaceutically acceptable salts are disclosed, including pharmaceutical compositions comprising the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, and/or with a pharmaceutically acceptable carrier. Methods of using the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative diseases, such as cancer, are also disclosed.
-
公开(公告)号：US11708381B2
公开(公告)日：2023-07-25
申请号：US16463135
申请日：2017-11-22
发明人： Guangdi Wang , Jiawang Liu , Shilong Zheng , Shanchun Guo
IPC分类号： C07F5/02 , C07C235/56 , C07C255/60
CPC分类号： C07F5/02 , C07C235/56 , C07C255/60
摘要： The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.
-
公开(公告)号：US20210323919A1
公开(公告)日：2021-10-21
申请号：US17232469
申请日：2021-04-16
IPC分类号： C07D209/56 , A61K45/06
摘要： The present disclosure relates to compounds that act as protein kinase inhibitors, especially RPS6K1 and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer, prostate cancer, lung cancer, and metastatic cancer.
-
公开(公告)号：US20210178287A1
公开(公告)日：2021-06-17
申请号：US17118319
申请日：2020-12-10
摘要： Disclosed are methods of solvent removal in an evacuated, closed system at ambient or low (spontaneously dropped due to evaporation endothermicity) temperature. The methods disclosed are suitable for removing the solvents with a broad range of volatility, having normal (STP) boiling points from 30 up to at least 202° C. (vapor pressures at least of 0.1 to 500 torr; higher boiling point solvents are possible to remove with longer experimental times) and is only limited from a volume standpoint by the size of the apparatus used.
-
公开(公告)号：US10112962B2
公开(公告)日：2018-10-30
申请号：US15323226
申请日：2015-07-01
发明人： Guangdi Wang , Qiu Zhong , Shilong Zheng
摘要： Boron-based prodrugs of phenol- or aromatic hydroxyl group-containing therapeutic molecules (“original drugs”), uses thereof, and methods of making the same, are provided for achieving, for example, improved bioavailability, prolonged retention (e.g., in a circulatory system) and, in particular, significantly lowered therapeutically effective dosage in order to reduce adverse effects while maintaining the desired therapeutic effects of the original drugs.
-
公开(公告)号：US10017475B2
公开(公告)日：2018-07-10
申请号：US15129785
申请日：2015-03-26
发明人： Guangdi Wang , Shilong Zheng , Qiu Zhong , Qiang Zhang
IPC分类号： A61K31/4418 , C07D213/61 , A61K45/06 , C07D213/30 , A61K31/4425
CPC分类号： C07D213/61 , A61K31/4418 , A61K31/4425 , A61K45/06 , C07D213/30
摘要： Combretastatins analog compounds and their pharmaceutically acceptable salts are presented, as well as pharmaceutical compositions comprising the combretastatin analog compounds and uses of the combretastatin analog compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of cancer, and in particular cancer presenting as metastatic tumors.
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.021 秒)
